NIH NATIONAL CANCER INSTITUTE

BUDGET FACT BOOK

FOR FISCAL YEAR 2021

U.S. Department of Health & Human Services
National Institutes of Health

TABLE OF CONTENTS

NCI Budget Fact Book

This report provides a summary of the distribution of the Fiscal Year 2021 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations.

Fiscal Year 2021 Highlights

Funds available to the NCI totaled $6.35 billion, post inter-departmental and intra-NIH transfers, including $50 million for the Childhood Cancer Data Initiative and $28 million for Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act. This reflects an increase of 1.6% and $99.3 million from the previous fiscal year.

Fiscal year highlights include:

- The Childhood Cancer Data Initiative (CCDI) will facilitate a connected data infrastructure and integrate multiple data sources to make data work better for patients, clinicians, and researchers.
- The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act, which was signed into law in June 2018, authorized funds for NCI to expand existing biorepositories for childhood cancer patients enrolled in NCI-sponsored clinical trials to collect and maintain relevant clinical, biological, and demographic information on children, adolescents, and young adults, and to continue to conduct and support pediatric cancer survivorship research.
- The 21st Century Cures Act, which was signed into law in December 2016, authorized $1.8 billion to fund the Cancer Moonshot over a 7-year period. The Cancer Moonshot funding received during Fiscal Year 2021 totaled $195 million.
- Of the total NCI budget obligated, 42.3% of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 5,210 (including grants funded through the Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) programs).
- Over one-fourth of the RPGs awarded were new (“Type 1”) or competing renewal (“Type 2”) awards.
- There was a total of 1,331 competing RPGs funded (excluding grants funded through SBIR & STTR).
- Almost one-third of the total NCI budget supported ongoing, non-competing (“Type 5”) RPGs.
- The R01 grants were funded to the 11th percentile for Experienced and New Investigators and the Early Stage Investigators were funded to the 16th percentile.
- R01 Early Stage Investigators between the 1st and 11th percentiles were converted to R37 awards giving them the opportunity to extend their research an additional 2 years.

- SBIR & STTR awards funded 238 grants totaling $158.3 million.
- Intramural Research comprised 16.8% of the total NCI budget.

The dollar amounts displayed in the NCI Budget Fact Book represent direct appropriated funds only, unless otherwise denoted.

Where to Find Information from Previous Fact Books

Information provided in previous Fact Books can now be found online. For example, view NCI's Organization Chart on the NIH Office of Management Assessment website. Cancer statistics can be found on the NCI website, as well as more detailed NCI Organization information. A limited number of Fact Books from prior years are available as hardcopy publications through the NCI Publications Locator. Find PDFs of all the NCI Budget Fact Books, dating back to 1971.

The NCI Budget Fact Book data is organized into the following sections. If you have any questions, please contact the Office of Budget and Finance (OBF).

NATIONAL CANCER INSTITUTE

Budget At A Glance: Fiscal Year 2021



NCI BUDGET INCREASED BY **$99.3 MILLION** (1.6%) FROM FISCAL YEAR 2020

42.3%
OF THE TOTAL NCI BUDGET ALLOCATED FOR RESEARCH PROJECT GRANTS

THE NATIONAL CANCER INSTITUTE (NCI) PROVIDES FUNDING AND SUPPORT FOR HEALTH-RELATED RESEARCH AND DEVELOPMENT THROUGH THE RPG (R01) GRANT MECHANISM.

R01 EARLY STAGE INVESTIGATORS BETWEEN THE 1ST AND 10TH **PERCENTILES** WERE CONVERTED TO **R37 AWARDS** GIVING THEM THE OPPORTUNITY TO EXTEND THEIR RESEARCH **AN ADDITIONAL 2 YEARS.**

OF RPG AWARDS WERE NEW (TYPE 1) OR COMPETING RENEWAL (TYPE 2) AWARDS

OF THE TOTAL NCI BUDGET SUPPORTED ONGOING, NON-COMPETING (TYPE 5) RPGs

1,331
NCI-FUNDED COMPETING RPGs

TOTALING OVER $158.3 MILLION FUNDED AS SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) AWARDS.

5,210
TOTAL NCI-FUNDED RPGs (INCLUDING SBIR & STTR)

cancer.gov
Source: 2021 NCI Budget Fact Book

NCI Budget Summary Data

This section of the NCI Budget Fact Book provides data about funds available to NCI and information on how NCI obligated its funding.

Most Recent Reported Fiscal Year Budget

In FY 2021, Congress passed a consolidated appropriations act allocating $6.365 billion to NCI, including $50 million for the Childhood Cancer Data Initiative (CCDI) and $28 million for Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act. NCI was also appropriated $195 million in FY 2021 as a result of the 21st Century Cures Act. After permissive transfers, $6.467 billion was available to NCI to obligate.

In addition to the appropriated amount for the fiscal year, NCI entered into inter- and intra-agency agreements with other Federal agencies and NIH institutes and centers (ICs). These agreements often provide reimbursements for materials, supplies, equipment, work, or services to assist other agencies and ICs accomplish their missions.

FISCAL YEAR 2021 BUDGET

(Whole Dollars)

Actual Obligations Resulting From Appropriated Funds	FY 2020 Amount
FY 2021 Appropriation	$6,364,852,000
FY 2021 Cancer Moonshot Appropriation	$195,000,000
Secretary's Transfer	-$19,109,000
Transfer to NIH Office of AIDS Research	-$1,047,000
Lapse	-$289,223
Cancer Moonshot Carryover	**-$96,671,541**
Actual Obligations Subtotal	$6,442,735,236
Reimbursable Obligations	**$24,294,730**
Total FY 2021 NCI Obligations	**$6,467,029,966**

Includes FY 2021 Cures Moonshot funding and excludes FYs 2020 through 2017 Cures Moonshot carryover obligations.

Funding Allocated to Major NCI Program Areas

Each fiscal year, NCI and other NIH institutes and centers report their obligations by mechanism. In addition to reporting by mechanism, reporting obligations by program structure is another way of showing how NCI obligates its funding each fiscal year.

For the purposes of reporting by program structure, NCI programs are categorized by budget activity. These budget activities include:

- Research – categorized by the following research thrusts: Childhood Cancer Data Initiative (CCDI), cancer causation; detection and diagnosis; treatment; and cancer biology
- Resource Development – cancer centers, research manpower development, and buildings and facilities
- Cancer Prevention and Control
- Program Management and Support



*Includes FY 2021 Cures Moonshot funding and excludes FYs 2019 through 2020 Cures Moonshot carryover obligations.

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/data/program-structure/program-structure-fy21.xlsx.

Extramural Funding

Overall, NCI obligations for its extramural program, which includes grants and contracts, totaled $4.88 billion in FY 2021.

- Obligations for grants totaled approximately 82.7% of extramural funding
- Obligations for contracts totaled approximately 17.3% of extramural funding

Obligations on this page include FY 2021 Cancer Moonshot funding and excludes fiscal years 2017 through 2020 Cures Moonshot carryover obligations.



View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/data/extramural/extramural-funds-fy21.xlsx.

EXTRAMURAL FUNDS, FISCAL YEAR 2021

(Whole Dollars)

Mechanism	Amount	Percent
Research & Development (R&D) Contracts	$812,246,516	16.7%
Buildings and Facilities	30,000,000	0.6%
Construction Contracts	0	0.0%
Subtotal Contracts	**$842,246,516**	**17.3%**
Research Project Grants (RPGs)	2,822,414,508	57.9%
Cancer Centers/Specialized Centers/SPORES	563,521,069	11.6%
NRSA	92,995,313	1.9%
Other Research Grants	556,149,380	11.4%
Subtotal Grants	**$4,035,080,270**	**82.7%**
Total Extramural Funds	**$4,877,326,786**	**100.0%**
Intramural/RMS Funds		*1,565,408,450*
Total NCI		**$6,442,735,236**

Obligations by Budget Mechanism and Division

All NIH Institutes and Centers report their actual obligations each fiscal year by budget mechanism. The tables below display NCI funding by mechanism and division. The number of awards, trainees, or employees for each mechanism, as well as the dollar amount and percent share of the total NCI budget for each funding mechanism is also included.

NCI Obligations by Mechanism



Other Research mechanisms includes the following grants: Career Programs (K Awards), Cancer Education, Clinical Cooperative Groups, Pre-Doc Post-Doc Transition Awards, Education Projects - Cooperative Agreements, Minority Biomedical Research Support, Research Pathway in Residency, Pilot Research Project, Resource Grants, International Research Training grants, Cooperative Conference Agreements, Conference grants, and Other Transaction Authority (OTA).

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/data/obligations/nci-obligation-by-mechanism-fy21.xlsx.

NCI OBLIGATIONS BY MECHANISM, FY 2021

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Research Project Grants (RPGs)	Non-Competing	3,641	$1,982,735,492	30.8%
	Administrative Supplements	283	40,531,153	0.6%
	Competing	1,331	640,878,364	9.9%
	Subtotal, without SBIR/ STTR Grants	4,972	$2,664,145,009	41.4%
	SBIR/STTR Grants	238	158,269,499	2.5%
	Subtotal, RPGs	**5,210**	**2,822,414,508**	**43.8%**
Centers & SPOREs	Cancer Centers Grants-P20/P30	32	344,697,904	5.4%
	SPOREs	64	119,570,354	1.9%
	Other P50s/P20s	57	3,306,038	0.1%
	Other Specialized Centers	79	95,946,773	1.5%
	Subtotal, Centers	**232**	**$563,521,069**	**8.7%**
Other Research	Career Program			
	Post-Doc-Fellow Awards-K00	78	7,211,442	0.1%
	Temin & Minority Mentored Awards-K01/ K43	35	5,573,009	0.1%
	Estab. Inv. Award-K-05	0	0	0.0%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	Preventive Oncology-K07	30	4,964,775	0.1%
	Clinical Investigator-K08	219	48,478,974	0.8%
	Clinical Oncology-K12	20	14,506,693	0.2%
	Transitional Career Development-K22	52	9,722,676	0.2%
	Mentored Patient Oriented RCDA-K23	3	534,675	0.0%
	Mid-Career Invest. & Patient Orient. Res-K24	2	354,197	0.0%
	Mentored Quant. Res Career-K25	1	157,167	0.0%
	Mentored Career Devel/ Tem Intl Career-K43	1	551,375	0.0%
	Pathway to Independence Awards K99	83	10,600,361	0.2%
	Subtotal, Career Program	524	$102,655,344	1.6%
	Cancer Education Program-R25(including BD2K)	68	17,632,838	0.3%
	Clinical Cooperative Groups-U10/UG1	106	299,980,858	4.7%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	PreDoc PostDoc Transition Awards-F99	44	1,770,090	0.0%
	UE5 Education Projects	5	2,045,516	0.0%
	Minority Biomedical Support-S06	0	1,497,039	0.0%
	Research Pathway in Residency (R38)	3	608,718	0.0%
	Pilot Research Project-OT2	1	3,308,166	0.1%
	Resource Grants-R24/U24/U2C	81	124,345,645	1.9%
	Cooperative Conference Agreements-U13/R13	25	434,014	0.0%
	Int'l Research Training Grants Conference-D43/U2R	4	1,871,152	0.0%
	Subtotal, Career and Other Research Grants	**861**	**$556,149,380**	**8.6%**
Subtotal, Research Grants		**6,303**	**$3,942,084,957**	**61.2%**
National Research Service Award (NRSA) Fellowships	Trainees	1,628	92,995,313	1.4%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
R&D Contracts	R&D Contracts	403	668,612,032	10.4%
	SBIR Contracts	44	20,916,852	0.3%
	NIH Management Fund/ SSF Assessment	0	122,717,632	1.9%
	Subtotal, Contracts	**403**	**$812,246,516**	**12.6%**
Intramural Research	Program		830,641,566	12.9%
	NIH Management Fund/ SSF Assessment		271,890,333	4.2%
	Subtotal, Intramural Research (FTEs)	**1,766**	**$1,102,531,899**	**17.1%**
Research Management & Support (RMS)	Research Management and Support (RMS)		350,205,851	5.4%
	SBIR RMS		3,056,688	0.0%
	NIH Management Fund/ SSF Assessment		109,614,012	1.7%
	Subtotal, RMS *(FTEs)*	**1,331**	**$462,876,551**	**7.2%**
Buildings & Facilities			30,000,000	0.5%
***Total NCI**	***(FTEs)***	**3,097**	**$6,442,735,236**	**100.0%**

All items in italics are non add entries.

**Includes FY 2021 Cures-Moonshot funding.*

**Excludes FY 2020 through FY 2017 Cures-Moonshot carryover obligations.*

Division Obligations by Mechanism

DIVISION OBLIGATIONS

Total Division Obligations, FY 2021

(Whole Dollars)

Division	Total
Center for Cancer Research (CCR)	$500,787,790
Division of Cancer Epidemiology and Genetics (DCEG)	107,110,008
Division of Cancer Treatment and Diagnosis (DCTD)	544,353,247
Division of Cancer Biology (DCB)	41,428,916
Division of Cancer Control and Population Sciences (DCCPS)	131,165,654
Division of Cancer Prevention (DCP)	223,216,237
Division of Extramural Activities (DEA)	19,737,071
Office of the Director (OD)	1,706,118,998
Total Division	**$5,841,398,976**

CENTER FOR CANCER RESEARCH (CCR)

CCR Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Intramural Research	Program	$500,787,790
	NIH Management Fund	0
Total CCR		**$500,787,790**

DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS (DCEG)

DCEG Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
R&D Contracts	R&D Contracts	$19,491,642
	SBIR Contracts	0
Intramural Research	Program	87,618,367
	NIH Management Fund	0
Total DCEG		**$107,110,008**

DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD)

DCTD Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	$0
	SPOREs-P50	110,212,968
	Other P50s/P20s	351,000
	Other Specialized Centers	8,513,327
	Subtotal, Centers	**$119,077,295**
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	0
	Clinical Cooperative Groups-U10/UG1	161,679,221
	PreDoc PostDoc Transition Awards-F99	0

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Grants	Education Projects-UE5	0
	Minority Biomedical Support-S06	0
	Rsrch Pathway in Residency-R38	0
	Pilot Research Project-OT2	0
	Resource Grants-R24/U24/U2C	0
	Cooperative Conference Agreements-U13/R13	0
	Int'l Research Training Grants-D43/U2R	0
	Subtotal, Other Research-Grants	**$161,679,221**
Subtotal, Research Grants		**$280,756,516**
R&D Contracts	R&D Contracts	201,622,622
	SBIR Contracts	0
	NIH Management Fund/SSF Assessment	0
	Subtotal, Contracts	**$201,622,622**

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Research Management & Support (RMS)	RMS	61,974,109
	SBIR RMS	0
	NIH Management Fund/SSF Assessment	0
	Subtotal, RMS	**$61,974,109**
Total DCTD		**$544,353,247**

DIVISION OF CANCER BIOLOGY (DCB)

DCB Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	$0
	SPOREs-P50	0
	Other P50s/P20s	300,688
	Other Specialized Centers	29,264,757
	Subtotal, Centers	**$29,565,445**
R&D Contracts	R&D Contracts	0
	SBIR Contracts	0
	NIH Management Fund/SSF Assessment	0
	Subtotal, Contracts	**$0**
Other Research-Grants	**Subtotal, Other Research–Grants**	**$0**
Research Management & Support (RMS)	RMS	11,863,471
	SBIR RMS	0
	NIH Management Fund	0
	Subtotal, RMS	**$11,863,471**
Total DCB		**$41,428,916**

DIVISION OF CANCER CONTROL AND POPULATION SCIENCES (DCCPS)

DCCPS Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	$0
	SPOREs-P50	0
	Other P50s/P20s	2,449,195
	Other Specialized Centers	0
	Subtotal, Centers	**$2,449,195**
Other Research	Cancer Education Program-R25 (including BD2K)	0
	Clinical Cooperative Groups-U10/UG1	0
	PreDoc PostDoc Transition Awards-F99	0
	Education Projects-UE5	0
	Minority Biomedical Support-S06	0
	Research Pathway in Residency-R38	0
	Pilot Research Project-OT2	0
	Resource Grants-R24/U24/U2C	184,250
	Cooperative Conference Agreements-U13/R13	0

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research	Int'l Research Training Grants-D43/U2R	0
	Subtotal, Other Research Grants	**$184,250**
Subtotal, Research Grants		**$2,633,445**
R&D Contracts	R&D Contracts	90,093,987
	SBIR Contracts	0
	Subtotal, Contracts	**$90,093,987**
Research Management & Support (RMS)	RMS	38,438,222
	SBIR RMS	0
	NIH Management Fund	0
	Subtotal, RMS	**$38,438,222**
Total DCCPS		**$131,165,654**

DIVISION OF CANCER PREVENTION (DCP)

DCP Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	$0
	SPOREs-P50	0
	Other P50s/P20s	0
	Other Specialized Centers	7,149,238
	Subtotal, Centers	**$7,149,238**
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	0
	Clinical Cooperative Groups-U10/UG1	129,370,923
	PreDoc PostDoc Transition Awards-F99	0
	UE5 Education Projects	0
	Minority Biomedical Support-S06	0
	Rsrch pathway in Residency-R38	0
	Pilot Research Project-OT2	0
	Resource Grants-R24/U24/U2C	0
	Cooperative Conference Agreements-U13/R13	0

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Grants	Int'l Research Training Grants-D43/U2R	0
	Subtotal, Other Research Grants	**$129,370,923**
Subtotal, Research Grants		**$136,520,161**
R&D Contracts	R&D Contracts	58,434,011
	SBIR Contracts	0
	NIH Management Fund/SSF Assessment	0
	Subtotal, Contracts	**$58,434,011**
Research Management & Support (RMS)	RMS	28,262,064
	SBIR RMS	0
	NIH Management Fund/SSF Assessment	0
	Subtotal, RMS	**$28,262,064**
Total DCP		**$223,216,237**

DIVISION OF EXTRAMURAL ACTIVITIES (DEA)

DEA Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Research Management & Support (RMS)	RMS	$19,737,071
	SBIR RMS	0
	NIH Management Fund	0
Total DEA		**$19,737,071**

OFFICE OF THE DIRECTOR (OD)

OD Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Research Project Grants (RPGs)	Non-Competing	$0
	Administrative Supplements	0
	Competing	0
	Subtotal, without SBIR/STTR Grants	$0
	SBIR/STTR Grants-R41 -44	158,269,499
	Subtotal, RPGs	**$158,269,499**

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	344,697,904
	SPOREs	9,357,386
	Other P50s/P20s	205,155
	Other Specialized Centers	50,569,123
	Subtotal, Centers	**$404,829,568**
Other Research–Career Program	Career Program	0
	Post-Doc-Fellow Awards-K00	7,211,442
	Temin & Minority Mentored Awards-K01	5,573,009
	Estab. Inv. Award-K05	0
	Preventive Oncology-K07	4,964,775
	Clinical Investigator-K08	48,478,974
	Clinical Oncology-K12	14,506,693
	Transitional Career Development-K22	9,722,676
	Mentored Patient Oriented RCDA-K23	534,675
	Mid-Career Invest. & Patient Orient. Res-K24	354,197
	Mentored Quant. Res Career-K25	157,167
	Mentored Career Devel/Tem Intl Career-K43	551,375

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Career Program	Pathway Award-K99	10,600,361
	Subtotal, Career Program	**$102,655,344**
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	17,632,838
	Clinical Cooperative Groups-U10/UG1	8,930,714
	PreDoc PostDoc Transition Awards-F99	1,770,090
	Education Projects-UE5	2,045,516
	Minority Biomedical Support-S06	1,497,039
	Rsrch Pathway in Residency-R38	608,718
	Other Transaction Authority-OT2	3,308,166
	Resource Grants-R24/U24/U2C	124,161,395
	Cooperative Conference Agreements-U13/R13	434,014
	Int'l Research Training Grants-D43/U2R	1,871,152
	Subtotal, Other Research–Grants	**$162,259,642**
Subtotal, Research Grants		**$828,014,053**

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
NRSA Fellowships		92,995,313
R&D Contracts	R&D Contracts	298,969,769
	SBIR Contracts	20,916,852
	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	Subtotal, Contracts	**$319,886,621**
Intramural Research	Program	242,235,410
	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	Subtotal, Intramural Research	**$242,235,410**
Research Management & Support (RMS)	RMS	189,930,914
	SBIR RMS	3,056,688
	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	Subtotal, RMS	**$192,987,602**
Buildings and Facilities		30,000,000
Total OD		**$1,706,118,998**

NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, social work, drug costs, red team response, bench to bedside and the Children's Hospital.

Center for Scientific Review: Initial scientific review of applications and assignment of research grant applications to institutes.

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services.

Service & Supply Fund: Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, biomedical engineering, background investigations, IT cybersecurity and GSA rental payments for space (to include all building rental costs, including utilities and guard services).



View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/data/management-fund/management-fund-fy21.xlsx.

NCI FY 2021 MANAGEMENT FUND, SSF, AND GSA RENT FY 2021

(Whole Dollars)

Distribution of NCI Payment	Amount	Share of NCI
Clinical Center	$172,120,358	38.0%
Center for Scientific Review	22,765,248	5.0%
Center for Information Technology	40,262,648	8.9%
Service & Supply Fund Assessment	205,569,289	45.3%
Other Research Services	12,777,921	2.8%
Other OD	0	0.0%
Total NCI Management Fund & SSF	**$453,495,464**	**100.0%**

NIH FY 2021 MANAGEMENT FUND & SSF

(Whole Dollars)

Type	Amount	Percent
NCI	$453,495,464	19.9%
Other NIH Institutes	$1,819,830,999	80.1%
Total NIH Management Fund & SSF	**$2,273,326,463**	**100%**

Special Sources of Funds

Cooperative Research and Development Agreements (CRADAs)

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Under a CRADA, the NIH laboratory can provide personnel, services, facilities, equipment or other resources and the collaborator can provide funds, personnel, services, facilities, equipment or other material and/or technical resources. Importantly, the CRADA provides the non-Federal party the option to negotiate an exclusive license to the resultant CRADA Subject Invention(s). The CRADA is the primary legal mechanism the Federal government has to convey such rights in advance of an invention. The agreement has no mandatory length but often are written for 1 to 3 years, renewable at the mutual agreement of the parties.

NCI CRADA RECEIPTS DEPOSITED TO THE U.S. TREASURY

(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2006	13,567	6,142	7,125
2007	12,584	9,410	8,360
2008	13,634	6,677	7,200
2009	13,111	5,466	4,765
2010	13,813	5,024	5,644
2011	13,150	8,582	5,894
2012	15,504	9,253	5,668
2013	10,587	11,226	8,470
2014	21,173	9,334	5,672
2015	24,835	15,772	11,670
2016	28,276	23,411	17,259
2017	40,647	27,033	20,990

(Continued from previous page)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2018	46,311	28,601	22,936
2019	50,978	32,899	28,178
2020	53,825	33,776	28,683
2021	59,044	38,735	32,994

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to support employees of the laboratory, further scientific exchange, and provide education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH. Royalties may be spent in the year of receipt and for two additional fiscal years.

NCI ROYALTY INCOME FUNDING HISTORY

(Dollars in Thousands)

Years	Collections*	Inventor Payments	Other Obligations
1991/1992	$2,084	$431	$1,653
2001/2003	27,443	6,210	21,233
2005/2007	34,086	5,745	28,341
2006/2008	29,811	6,853	22,958
2007/2009	36,344	7,210	29,134
2008/2010	50,269	8,192	42,077
2009/2011	51,621	10,225	41,396
2010/2012	58,515	5,729	52,786

(Continued from previous page)

Years	Collections*	Inventor Payments	Other Obligations
2011/2013	69,155	23,271	45,884
2012/2014	84,876	33,279	51,597
2013/2015	91,324	48,433	42,891
2014/2016	112,668	33,487	79,181
2015/2017	122,037	30,605	91,432
2016/2018	115,096	27,316	87,780
2017/2019	112,611	27,233	85,378
2018/2020	86,231	15,539	70,692
2019/2021	70,400	5,370	65,030
**2020/2022	30,850	8,000	22,850
**2021/2023	35,000	8,000	27,000

** Collections do not include assessments by NIH.*

*** 2020/2022 and 2021/2023 Inventor Payments and Other Obligations are estimates.*

Stamp Out Breast Cancer Act

The Stamp Out Breast Cancer Act (PL 105-41) was enacted in August 1997 and has since been extended to July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), December 2011 (PL 112-80), December 2015 (PL 114-99) and recently until December 2027 (PL 116-92). This act allows postal customers the opportunity to contribute funds to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service (USPS). Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2020, NCI has received $63,225,028. NCI uses these funds for research projects directed towards breast cancer research. Thus far, five major programs have been funded, including the Insight Awards to Stamp Out Breast Cancer, the Breast Cancer Research Stamp Exceptional Opportunities Program, the Breast Cancer Premalignancy Program, a clinical trial to determine the risk of breast cancer recurrence, the Molecular and Cellular Characterization of Screen Detected Lesions Consortium, the Breast Cancer Weight Loss (BWEL), and the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). In FY 2021, $1,000,000 million in Stamp funds were obligated towards Breast Cancer research.

NCI BREAST CANCER STAMP FUNDING HISTORY

(Dollars in Thousands)

FY	Collected	Obligated	*Balance
1999	4,150	0	4,150
2000	3,101	3,499	3,753
2001	5,556	4,846	4,463
2002	3,595	1,129	6,929
2003	5,176	3,130	8,975
2004	4,814	3,472	10,317
2005	4,372	2,987	11,703
2006	4,468	6,896	9,274
2007	3,006	1,601	10,679
2008	4,856	2,122	13,413

(Continued from previous page)

FY	Collected	Obligated	*Balance
2009	3,403	1,873	14,944
2010	2,345	2,590	14,698
2011	2,049	1,977	14,770
2012	1,623	1,654	14,738
2013	1,404	1,337	14,805
2014	1,160	1,477	14,488
2015	1,251	1,635	14,105
2016	1,707	1,654	14,158
2017	1,387	1,640	13,905
2018	1,294	5,349	16,497
2019	1,450	2,518	15,429
2020	1,060	2,571	13,918
2021	1,112	1,000	14,030

**Balance includes carryover funds from the prior fiscal year that have not obligated.*

Funding for Research Areas

The National Cancer Institute reports how appropriated funds are spent based on different categories or classifications, including specific cancer sites, cancer types, diseases related to cancer, as well as types of NCI research mechanisms. The table below identifies funding levels for frequently requested areas of cancer research.

The research areas in this table do not represent the entire NCI research portfolio. Moreover, funding for research areas often overlap, and therefore the total for all research areas does not add to the total NCI budget. For example, funding for a clinical trial on breast cancer would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine, and ovarian cancers, and relevant amounts would be included in the amounts for all three areas of cancer research. NCI provides estimated amounts based on initial budget data before final reconciliation is completed. After this analysis is done, years are marked Actual where figured often vary slightly from previously reported estimates.

FUNDING BY RESEARCH AREAS

(Dollars in Millions)

Disease Area	2015 Actual	2016 Actual	2017 Actual	2018 Actual	2019 Estimate	2020 Estimate
Total NCI Budget	**$4,952.6**	**$5,206.2**	**$5,636.4**	**$5,927.7**	**$6,440.4**	**$6,440.4**
AIDS	269.7	266.4	249.0	241.2	242.0	242.0
Brain & CNS	204.8	196.3	219.8	220.9	231.7	595.1
Breast Cancer	543.6	520.1	545.1	574.9	545.3	514.6
Cervical Cancer	57.1	65.6	68.0	71.5	86.0	69.3
Clinical Trials	748.0	801.0	806.6	889.8	794.3	843.0
Colorectal Cancer	209.3	212.2	208.4	256.0	238.8	211.6
Head & Neck Cancers	60.2	58.9	63.6	62.1	71.5	49.7
Hodgkin Disease	13.6	12.8	13.0	13.3	12.2	14.3
Leukemia	246.9	241.0	250.5	258.3	256.6	244.5

(Continued from previous page)

Disease Area	2015 Actual	2016 Actual	2017 Actual	2018 Actual	2019 Estimate	2020 Estimate
Liver Cancer	70.3	75.7	72.7	94.6	107.8	96.3
Lung Cancer	255.8	283.8	320.6	350.1	418.4	402.8
Melanoma	132.8	142.9	153.2	158.4	191.9	155.6
Multiple Myeloma	48.9	52.1	60.7	61.5	58.2	43.3
Non-Hodgkin Lymphoma	122.4	116.7	119.5	121.0	120.4	119.5
Ovarian Cancer	92.8	95.3	109.8	120.8	121.5	116.5
Pancreatic Cancer	125.3	152.6	178.3	182.1	187.0	178.5
Prostate Cancer	228.9	241.0	233.0	239.1	244.8	209.4
Stomach Cancer	13.5	13.3	13.4	14.2	14.8	10.6
Uterine Cancer	13.0	16.8	17.5	17.5	17.9	13.6

These figures were created using NCI's coding methodology. More information about this methodology, as well as the research projects associated with these and other disease area categories, are available on the NCI Funded Research Portfolio website.

The FY 2020 funds available to the NCI totaled $6.4 billion (includes $195 million in CURES Act funding), reflecting an increase of 9.2 percent, or $524 million from the previous fiscal year. Under the NCI RPG funding policy for FY 2020, non-competing grants were awarded with a 3 percent reduction from the committed level. For more information on NCI's grant funding policy, visit the NCI Division of Extramural Activities website.

NCI Extramural Programs

The NCI uses most of its budget to fund extramural grants and contracts. The following links provide information about Fiscal Year 2021 extramural funding by grant activity, institution, state, and country.

Research Project Grants (RPGs)

During fiscal year 2021,

- Over 72% of competing dollars supported grants awarded within the established payline and RFAs and the remainder supported grants as an exception to the fundable range.
- RFA funds accounted for 13.1% of the FY 2021 competing dollars.
- A total of 1,331 competing RPGs were funded.

The FY 2020 figures include FY 2020 Cancer Moonshot funds and the FY 2021 figures include FY 2021 Cancer Moonshot funds.

The FY 2021 competing RPG average cost calculation includes multi-year funded grants with a 1 year average cost estimation.



Includes Small Business Innovation Research and Small Business Technology Transfer Awards. Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/extramural-programs/rpg/rpg-number-awards-fy21.xlsx.

RPGs Summary, FY 2020-2021

RPG AWARDS FUNDED

(Dollars in Thousands)

RPG Awards Funded	2020 No. or %	2020 Amount	2021 No. or %	2021 Amount
Total Funding for RPGs	**5,070**	**2,771,666**	**5,210**	**2,822,415**
SBIR/STTR	217	151,141	238	158,269
Funding for RPGs without SBIR/STTR Program	4,853	2,620,526	4,972	2,664,145
Continuation or Noncompeting Grants Funded	3,636	1,814,161	3,641	1,886,072
Competing Grants Funded	1,217	681,401	1,331	640,878
Administrative Supplements	221	30,503	283	40,531
Partial Assessment for DHHS Program Evaluation		94,460		96,664

FUNDS SET ASIDE WITHIN COMPETING DOLLARS

(Dollars in Thousands)

Grant Category	R01 or Share	2020 No. or %	2020 Amount	2021 No. or %	2021 Amount
Grants within Paylines		933	409,440	1,007	440,021
	Traditional R01	714	352,832	733	376,081
RFA Grants		93	143,328	151	83,636

(Continued from previous page)

Grant Category	R01 or Share	2020 No. or %	2020 Amount	2021 No. or %	2021 Amount
	Share of Competing Grant Funds	21.0%		13.1%	
Exception Grants		284	271,961	324	200,857
	Share of Competing Grant Funds	39.9%		31.3%	

COMPETING RPGS

Statistical Measure	2020	2021
Total Competing Application Requests*	9,538	9,601
Funding Success Rate	13%	14%
Percentile Funding for R01 Grants	10th & 15th	11th & 16th
Average Cost-Competing**	$503	$486
Average Reduction from Recommended/Requested Levels	-14%	-14%

**Excludes SBIR/STTR*

***The FY 2021 competing RPG average cost calculation includes multi-year funded grants with a 1 year average cost estimation.*

FY 2020 figures include FY 2020 Cancer Moonshot funds.

FY 2021 figures include FY 2021 Cancer Moonshot funds.

RPGs Funding Mechanisms



The "Other" category includes DP1, DP2, DP5, R00, R37, U01, U19, UH2, UH3, UG3, UA5, R50, UM1, R15, R55 and R56 grant activities.

Includes fiscal years 2020 and 2021 Cancer Moonshot funding and excludes all carryover obligations.

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/extramural-programs/rpg/rpg-funding-paylines-fy21.xlsx.

GRANT FUNDING PAYLINES

RPG Mechanism	2020	2021	Description
R01 Traditional Grants	10th & 15th	11th & 16th	Percentile
P01 Program Projects	17% Reduction	17% Reduction	SPL Selected*
R03 Small Grants	25	25	Impact Score
R15 Academic Research	25	25	Impact Score
R21 Exploratory Phase I	9th	9th	Percentile
R33 Exploratory Phase II	N/A	N/A	SPL Selected*
R41/R42 STTR	26	28	Impact Score
R43/R44 SBIR	25	22	Impact Score

**SPL = Scientific Program Leaders (NCI)*

RPGs Requested and Awarded

The following table displays requested and awarded RPGs and the success rate for fiscal years 2019 and 2020. These numbers include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) awards. The Download the Data link contains data for the prior ten years.

RPGS REQUESTED, AWARDED, AND SUCCESS RATE

(Dollars in Thousands)

Fiscal Year	Type	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
2020	Competing New	10,361	$4,866,693	1,210	$595,825	12.4%
	Competing Renewal	463	385,101	136	161,312	
	Competing Supplement	28	7,485	4	885	
	Competing Subtotal	**10,852**	**5,259,279**	**1,350**	**758,022**	
	Non-Competing			3,720	2,013,645	
	FY 2020 RPG Total			**5,070**	**$2,771,666**	
2021	Competing New	10,080	$4,935,665	1,336	$630,816	14.1%
	Competing Renewal	409	289,208	141	93,308	
	Competing Supplement	39	16,065	9	2,875	
	Competing Subtotal	**10,528**	**5,240,938**	**1,486**	**726,998**	

(Continued from previous page)

Fiscal Year	Type	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
	Non-Competing			3,724	2,095,416	
	FY 2021 RPG Total			**5,210**	**$2,822,415**	

Includes Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) Awards.

Success rate is the number of awarded grants divided by the number of awards requested.

Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.

RPG Awards by Grant Activity Codes

This table displays awarded research project grants (RPG) data by grant activity code and count. Please visit NIH Activity Codes for more information on the descriptions.

RPGS AVERAGE COST, FY 2011–2021

(Dollars in Thousands)

Year	Total No. Awarded	Total Amount	Average Cost
2011	5,019	$2, 088,352	$416
2012	5,021	$2,075,295	$413
2013	4,816	$1,924,803	$400
2014	4,814	$1,939,623	$403
2015	4,767	$2,019,308	$424
2016	4,666	$2,068,869	$443
*2017	4,663	$2,195,184	$471
*2018	4,780	$2,366,530	$495
*2019	4,984	$2,456,156	$493
*2020	5,070	$2,677,206	$514
**2021	5,210	$2,725,751	$523

RPG Activity Codes with a "0" count displayed for No. are grants where NCI did not take the grant award count for the funding since NCI was not the Primary IC funding the award.

From FY 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall.

**Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.*

***Fiscal year 2021 includes multi-year funded grants with a 1 year average cost estimation.*

RPG AWARDS BY GRANT ACTIVITY CODES, FY 2019-2020

(Dollars in Thousands)

Grant Code	2020 Number	2020 Amount	2021 Number	2021 Amount
R01	3,316	$1,555,105	3,448	$1,622,714
DP1	1	1,197	0	0
DP2	0	0	0	0
DP5	0	0	0	0
P01	93	187,766	96	196,613
R00	95	23,566	78	18,841
R37	156	71,569	220	100,632
*RFA	0	0	0	0
U01	300	257,018	304	238,270
U19	2	6,335	6	10,052
UH2	7	1,573	7	1,603
R35	154	145,771	166	158,472
R50	96	15,799	77	12,889
UH3	36	20,106	29	19,204
UA5	0	0	0	0
UM1	23	102,669	15	55,880
UG3	8	4,387	13	10,917
R03	119	11,689	93	8,383
R21	387	92,517	367	89,334

(Continued from previous page)

Grant Code	2020 Number	2020 Amount	2021 Number	2021 Amount
R33	37	19,351	34	16,535
R15	22	9,299	18	7,018
R55	0	0	0	0
R56	1	345	1	122
RC2	0	0	0	0
SBIR/STTR	217	151,141	238	158,269
Total	**5,070**	**$2,677,206**	**5,210**	**$2,725,751**

RPG Activity Codes with a "0" count displayed for No. are grants where NCI did not take the grant award count for the funding since NCI was not the Primary IC funding the award.

From FY 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall.

Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2020.

Fiscal year 2021 includes multi-year funded grants with a 1 year average cost estimation.

Grants to NCI-Designated Cancer Centers

NCI-designated cancer centers are institutions dedicated to research to develop more effective approaches to prevent, diagnose, and treat cancer. Find an NCI designated cancer center near you and learn about its patient services and research capabilities.

The grant count and amounts include multi-year funded awards and the FY 2021 Cancer Moonshot funds, excludes carryover obligations for fiscal years 2017 through 2020.

NCI-DESIGNATED CANCER CENTER TOTALS, FY 2021

(Dollars in Thousands)

Mechanism	Count	Amount
*Total P30 Core Grants	71	$329,505
Planning Grants (P20s)	16	4,473
**Other Cancer Center Grants	0	10,719
Total Cancer Centers	**87**	**$344,697**

**Includes multi-year funded awards and FY 2021 Cancer Moonshot funds, excludes carryover obligations for fiscal years 2017 through 2020.*

***Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy, updated each fiscal year with limits based on the cost center and division; this category is to be reported as zero.*

NCI-DESIGNATED CANCER CENTERS BY STATE (P30 CORE GRANTS), FY 2021

(Dollars in Thousands)

State	Grantee Institution	Code	Count	Amount
Alabama	University of Alabama at Birmingham	Comprehensive Core	1	$5,155
Arizona	University of Arizona	Comprehensive Core	1	4,459
California	Beckman Research Institute/City of Hope	Comprehensive Core	1	3,928
	Salk Institute for Biological Studies	Basic Core	1	3,067
	Sanford Burnham Prenys Medical Discovery Institute	Basic Core	1	4,082
	Stanford University	Comprehensive Core	1	3,454
	University of California Davis	Comprehensive Core	1	3,501
	University of California Los Angeles	Comprehensive Core	1	5,517
	University of California San Diego	Comprehensive Core	1	5,258
	University of California San Francisco	Comprehensive Core	1	8,627
	University of California Irvine	Comprehensive Core	1	0
	University of Southern California	Comprehensive Core	1	6,282

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Colorado	University of Colorado Denver	Comprehensive Core	1	4,086
Connecticut	Yale University	Comprehensive Core	1	4,712
District of Columbia	Georgetown University	Comprehensive Core	1	2,652
Florida	H. Lee Moffitt Cancer Center & Research Institute	Comprehensive Core	1	3,119
	University of Miami School of Medicine	Clinical Core	1	2,272
Georgia	Emory University	Comprehensive Core	1	2,724
Hawaii	University of Hawaii at Manoa	Clinical Core	1	2,156
Illinois	Northwestern University at Chicago	Comprehensive Core	1	6,708
	University of Chicago	Comprehensive Core	1	4,533
Indiana	Indiana Univ-Purdue Univ at Indianapolis	Comprehensive Core	1	3,246
	Purdue University West Lafayette	Basic Core	1	1,860
Iowa	University of Iowa	Comprehensive Core	1	3,077

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Kansas	University of Kansas Medical Center	Clinical Core	1	2,272
Kentucky	University of Kentucky	Clinical Core	1	2,303
Maine	Jackson Laboratory	Basic Core	1	2,459
Maryland	Johns Hopkins University	Comprehensive Core	1	7,721
	University of Maryland Baltimore	Comprehensive Core	1	3,158
Massachusetts	Dana-Farber Cancer Institute	Comprehensive Core	1	12,615
	Massachusetts Institute of Technology	Basic Core	1	3,755
Michigan	University of Michigan at Ann Arbor	Comprehensive Core	1	7,020
	Wayne State University	Comprehensive Core	1	2,889
Minnesota	Mayo Clinic in Rochester	Comprehensive Core	1	5,980
	University of Minnesota	Comprehensive Core	1	4,176
Missouri	Washington University	Comprehensive Core	1	6,346
Nebraska	University of Nebraska Medical Center	Clinical Core	1	2,395

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
New Hampshire	Dartmouth College	Comprehensive Core	1	3,401
New Jersey	Rutgers Cancer Institute of New Jersey	Comprehensive Core	1	3,325
New Mexico	University of New Mexico Health Science Center	Comprehensive Core	1	3,508
New York	Albert Einstein College of Medicine Yeshiva University	Clinical Core	1	3,405
	Cold Spring Harbor Laboratory	Basic Core	1	4,495
	Columbia University Health Sciences	Comprehensive Core	1	5,552
	Ichan School of Medicine at Mount Sinai	Clinical Core	1	3,138
	New York University School of Medicine	Comprehensive Core	1	4,196
	Roswell Park Cancer Institute Corp	Comprehensive Core	1	4,776
	Memorial Sloan-Kettering Institute for Cancer Research	Comprehensive Core	1	14,147

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
North Carolina	Duke University	Comprehensive Core	1	6,519
	University of North Carolina Chapel Hill	Comprehensive Core	1	8,216
	Wake Forest University Health Sciences	Comprehensive Core	1	2,438
Ohio	Case Western Reserve University	Comprehensive Core	1	5,746
	Ohio State University	Comprehensive Core	1	6,027
Oklahoma	University Of Oklahoma Health Sciences Center	Clinical Core	1	2,956
Oregon	Oregon Health and Science University	Comprehensive Core	1	2,710
Pennsylvania	Research Institute of Fox Chase Cancer Center	Comprehensive Core	1	1,435
	Thomas Jefferson University	Clinical Core	1	2,874
	University of Pennsylvania	Comprehensive Core	1	9,736
	University of Pittsburgh at Pittsburgh	Comprehensive Core	1	6,034
	Wistar Institute	Basic Core	1	2,715
South Carolina	Medical University of South Carolina	Clinical Core	1	2,156

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Tennessee	St. Jude Children's Research Hospital	Comprehensive Core	1	6,618
	Vanderbilt University	Comprehensive Core	1	8,071
Texas	Baylor College of Medicine	Comprehensive Core	1	3,916
	University of Texas Health Science Center	Clinical Core	1	2,392
	University of Texas M.D. Anderson Cancer Center	Comprehensive Core	1	11,893
	University of Texas Southwestern Medical Center	Comprehensive Core	1	4,306
Utah	University of Utah	Comprehensive Core	1	4,487
Virginia	University of Virginia	Clinical Core	1	2,603
	Virginia Commonwealth University	Clinical Core	1	2,174
Washington	Fred Hutchinson Cancer Research Center	Comprehensive Core	1	10,770
Wisconsin	University of Wisconsin-Madison	Comprehensive Core	1	5,206
Total P30 Core Grants			**71**	**329,505**

Specialized Programs of Research Excellence (SPOREs)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). Each SPORE focuses on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. Total funding shown represents the SPORE program using relevant P50s, P20s, and co-funded grants external to NCI.

The Translational Research Program (TRP) is the home of the SPOREs, a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis, and treatment of human cancers. For more information on these SPORE grants and organ sites, please visit the Translational Research Program.

The NCI Funded Research Portfolio (NFRP) web site contains additional information about the SPORE grants listed below that have been funded by NCI. The NFRP provides access to various NCI budget reports that contain information about research funding according to specific research categories. For more detailed information on all SPORE grants, please visit the NCI Funded Research Portfolio.

FY 2021 FUNDING FOR SPORE GRANTS

(Whole Dollars)

Mechanism	Site	Amount
P50 & P20 SPOREs	Bladder	2,138,532
	Brain	12,605,338
	Breast	11,987,567
	Cervical	1,668,414
	Epigenetic	2,269,729
	Gastrointestinal	2,273,000
	GI	9,645,663
	Head and Neck	1,640,453
	Head and Neck, GI	1,125,482
	Hyperactive RAS	2,198,683
	Kidney	2,272,484
	Leukemia	9,338,627
	Liver	5,353,668
	Lung	10,576,724
	Lung, GI, Breast, H&N	1,067,994
	Lymphoma	6,756,476
	Multiple Myeloma	4,348,414
	Neuroendocrine	500,000
	Ovarian	9,734,411
	Ovarian, Endometrial	1,023,100

(Continued from previous page)

Mechanism	Site	Amount
P50 & P20 SPOREs	Prostate	9,823,748
	Sarcoma	2,126,450
	Skin	10,939,837
	Total P50 SPOREs	**$121,414,794**
Co-funded	Head & Neck	$575,000
	Total Co-funded	**$575,000**
Total Number of SPOREs, Total SPORE Funding		**$121,989,794**

Dr. Ruth L. Kirschstein National Research Service Awards (NRSA)

This trainee award program is named after Dr. Ruth L. Kirschstein, a polio vaccine researcher and a champion of research training and inclusion of underrepresented individuals in the scientific workforce. Dr. Kirschstein was the first woman to become director of an NIH institute.

The NCI Ruth L. Kirschstein National Research Service Award (NRSA) program helps ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to meet the Nation's biomedical, behavioral, and clinical research needs.



Data for fiscal years 2014 and 2015 in previous editions of the NCI Budget Fact Book reported the total number of "Individual" and "Institutional" awards instead of the total number of Predoctoral and Postdoctoral full-time training positions. This table has been updated with the correct data.

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/extramural-programs/nrsa/nrsa-fy21.xlsx.

Research Career Awards "K" Program

The NCI career development (K) awards program includes a broad range of funding mechanisms and provides scientists with support to further develop their cancer research careers, transition to independence, expand their existing research programs, or mentor junior investigators. The K awards are a significant component of NCI's training effort.



View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/extramural-programs/k-awards/k-awards-fy21.xlsx.

Percent of Total Research Career Awards Funded

Fiscal Year 2021



- K00 Post-Doc-Fellow Awards
- K01 Research Scientist Development Award
- K05 Research Scientist Award
- K07 Preventive Oncology
- K08 Clinical Investigator
- K12 Institutional Clinical Oncology Research
- K22 Transitional Career Development
- K23 Patient-Oriented Career
- K24 Patient-Oriented Career - Mid Career
- K25 Mentored Quantitative Research Career Development Award
- K43 Mentored Career Devel/Temin Intl Career
- K99 NIH Pathway to Independence Awards

cancer.gov

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/extramural-programs/k-awards/k-awards-fy21.xlsx.

Grant and Contract Awards

The following displays the number and dollar amount of grant and contract awards by state and country with details for institutions receiving more than $15 million in support from NCI.

Grants are used when no substantial programmatic involvement is anticipated between the NCI and the grant recipient during performance of the financially assisted activities and when there is no expectation on the part of the NCI of a specified service or product for NCI.

Contracts are used to procure cancer research services and other resources that the Federal government needs to advance the NCI cancer research mission.

Grant and contract data includes FY 2021 Cancer Moonshot funds and excludes FYs 2017 through 2020 Cancer Moonshot carryover obligations, Breast Cancer Stamp, NRSA tap, the Loan Repayment Program, Program Evaluation, and other assessments. Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy are updated each fiscal year with limits based on the cost center and division. A "0" indicates an award funded by other NIH Institutes that NCI also co-funded.

Grant and Contract Awards by State and Institution

In the map graphic below, grant and contract awards are presented by state. The table below the graphic provides information for U.S. territories. Within each state, hover to view the total amount awarded and click to view detailed data on institutions that received more than $15 million in support from NCI during FY 2021. For purposes of the Fact Book, institutions include universities, cancer centers, and hospitals.

Grant and Contract Awards by State and Institution, FY 2021



Other category represents total grant and contract funding in that state for all remaining organizations including universities, cancer centers, and hospitals who receive less than $15 million in NCI support.

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/extramural-programs/cancer-centers/p30-cancer-centers-by-state-fy21.xlsx.

GRANT AWARDS BY STATE, FY 2021

(Whole Dollars)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Alabama	67	$36,714,200	2	$609,176	69	$37,323,376
Alaska	1	$784,322	0	$0	1	$784,322

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Arizona	56	$40,139,491	2	$345,067	58	$40,484,558
Arkansas	22	$7,633,357	2	$56,000	24	$7,689,357
California	970	$594,687,856	20	$23,757,753	990	$618,445,609
Colorado	98	$37,769,184	1	$1,000	99	$37,770,184
Connecticut	124	$57,681,665	2	$3,170,248	126	$60,851,913
Delaware	6	$5,157,832	0	$0	6	$5,157,832
Dist Of Col	69	$34,215,156	9	$3,294,378	78	$37,509,534
Florida	200	$92,259,734	4	$2,465,477	204	$94,725,211
Georgia	122	$55,011,549	5	$5,284,513	127	$60,296,062
Hawaii	17	$14,729,016	1	$1,557,557	18	$16,286,573
Idaho	0	$0	1	$521,188	1	$521,188
Illinois	250	$136,009,783	12	$7,626,037	262	$143,635,820
Indiana	82	$36,646,382	1	$136,666	83	$36,783,048
Iowa	34	$22,562,761	1	$4,162,658	35	$26,725,419
Kansas	15	$9,743,738	0	$0	15	$9,743,738
Kentucky	54	$22,427,109	2	$2,723,444	56	$25,150,553
Louisiana	28	$10,763,030	1	$1,772,202	29	$12,535,232
Maine	20	$11,845,729	0	$0	20	$11,845,729
Maryland	192	$97,619,193	46	$518,828,181	238	$616,447,374
Massachusetts	725	$406,169,072	6	$5,940,126	731	$412,109,198
Michigan	205	$105,536,540	3	$53,087	208	$105,589,627

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Minnesota	164	$98,740,990	7	$1,575,739	171	$100,316,729
Mississippi	1	$397,445	0	$0	1	$397,445
Missouri	138	$76,735,643	4	$4,391,995	142	$81,127,638
Montana	3	$1,388,885	0	$0	3	$1,388,885
Nebraska	43	$20,863,288	0	$0	43	$20,863,288
Nevada	3	$2,259,468	0	$0	3	$2,259,468
New Hampshire	34	$17,839,375	2	$56,000	36	$17,895,375
New Jersey	78	$40,776,237	4	$11,212,602	82	$51,988,839
New Mexico	19	$13,076,176	1	$2,649,530	20	$15,725,706
New York	852	$478,732,591	6	$9,243,747	858	$487,976,338
North Carolina	271	$139,901,504	5	$1,615,708	276	$141,517,212
Ohio	258	$129,653,558	5	$1,433,807	263	$131,087,365
Oklahoma	34	$16,255,858	2	$2,289,369	36	$18,545,227
Oregon	82	$57,231,938	1	$1,000	83	$57,232,938
Pennsylvania	467	$270,163,068	4	$366,422	471	$270,529,490
Rhode Island	17	$6,553,180	0	$0	17	$6,553,180
South Carolina	62	$34,396,472	0	$0	62	$34,396,472
South Dakota	3	$1,416,538	0	$0	3	$1,416,538
Tennessee	183	$108,001,670	5	$3,958,571	188	$111,960,241
Texas	559	$275,706,465	4	$4,723,822	563	$280,430,287

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Utah	81	$32,501,856	2	$2,585,808	83	$35,087,664
Vermont	9	$6,303,528	2	$419,715	11	$6,723,243
Virginia	95	$53,081,747	20	$50,676,441	115	$103,758,188
Washington	219	$152,470,779	5	$6,209,625	224	$158,680,404
West Virginia	6	$1,386,871	0	$0	6	$1,386,871
Wisconsin	106	$71,302,138	3	$1,611,525	109	$72,913,663
Wyoming	1	$186,018	0	$0	1	$186,018

GRANT AWARDS BY TERRITORY, FY 2021

(Whole Dollars)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Guam	1	$1,422,643	0	$0	1	$1,532,165
Puerto Rico	7	$5,657,267	0	$0	7	$5,929,207

Grant and Contract Awards by Country

NCI funds and co-funds cancer research all over the world. The table below lists number and dollar amount of grant and contract awards by country.

GRANT AND CONTRACT AWARDS BY COUNTRY, FY 2021

(Whole Dollars)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Argentina	1	$155,024	0	$0	1	$155,024
Australia	4	2,837,312	0	0	4	2,837,312
Belarus	0	0	1	153,832	1	153,832
Canada	11	6,648,386	0	0	11	6,648,386
Costa Rica	0	0	1	835,869	1	835,869
Denmark	1	406,906	0	0	1	406,906
France	6	4,283,732	0	0	6	4,283,732
Germany	1	1,032,409	0	0	1	1,032,409
Jamaica	0	50,000	0	0	0	50,000
Nigeria	0	170,447	0	0	0	170,447
South Africa	3	595,566	0	0	3	595,566
Sweden	2	415,814	0	0	2	415,814
Switzerland	0	297,329	0	0	0	297,329
Tanzania U Rep	0	75,000	0	0	0	75,000

(Continued from previous page)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Uganda	0	98,034	0	0	0	98,034
United Kingdom	3	1,666,276	0	0	3	1,666,276
Zambia	0	80,028	0	0	0	80,028
Total	**32**	**$18,812,263**	**2**	**$989,701**	**34**	**$19,801,964**

NCI Historical Trends

Established in 1937, the National Cancer Institute (NCI) was among the first Institutes of the National Institutes of Health (NIH). From the outset, NCI served as a scientific cornerstone of the NIH. The following links provide information about the history of NCI appropriations and the Professional Judgment (Bypass) Budget, as well as data on funding trends and staffing levels.

NCI Professional Judgment Budget, President's Budget and Appropriations

Professional Judgment Budget, President's Budget and Enacted Appropriations Comparison

This graph displays a historical view of the Professional Judgment Budget, the President's Budget, and the Enacted Appropriations for the NCI from fiscal years 1974 through 2023. The National Cancer Act gives the NCI Director special authority to submit an annual Professional Judgment Budget, sometimes referred to as the "Bypass Budget," directly to the President and Congress. This budget reflects NCI cancer research priorities and identifies areas of potential investment in cancer research. The President's Budget is an annual report prepared by the White House, and in coordination with federal agencies, proposing funding levels for the federal government, including for the NIH and NCI, according to the President's priorities. Congress reviews the Professional Judgment Budget and the President's Budget, and then conducts its own inquiries and hearings to develop and pass an appropriations bill to fund the government. When the bill is signed into law by the President, the Enacted Appropriation levels become available for NCI's cancer research activities.



- The Professional Judgment Budget was not released in FY 2014, FY 2015, or in FY 2018. To learn more about this authority and view the budget archive, please visit NCI's About the Annual Plan and Budget Proposal page.
- The FY 2017 and FY 2018 Enacted Appropriated budget includes $300,000,000 of Cancer Moonshot℠ funding. $680,000,000 and $300,000,000 of Cancer Moonshot℠ funding are also included in the FY 2017 and FY 2018 President's Budget. $400,000,000, $195,000,000, $195,000,000 of Cancer Moonshot℠ funding are included in the FY 2019, FY 2020, and FY 2021 Enacted Appropriated levels, respectively. The Professional Judgment Budget and President's Budget also includes $400,000,000, $195,000,000, $195,000,000, $194,000,000 of Cancer Moonshot℠ funding in fiscal years 2019, 2020, 2021, and 2022 respectively.
- The Enacted Appropriation levels do not include potential adjustments such as Rescissions, Sequestrations, Supplemental funding, or Secretary's Transfers that may have impacted the amount available for NCI expenditure.

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/historical-trends/bypass-appropriations/professional-judgement-presidents-budget-enacted-fy21.xlsx.

NCI Appropriations

NCI receives its budget from the United States Congress as part of the federal budget process for the Department of Health and Human Services and NIH.

The NCI budget for FY 2021 (October 1, 2020 through September 30, 2021) is $6.56 billion. During the period from 2010 through 2021, the NCI budget averaged $5.52 billion per year.

APPROPRIATIONS OF THE NCI, 1938–2021

(Whole Dollars)

Fiscal Years	Amount	Notes
1938 - 2002	**$52,940,982,220**	
2003	4,622,394,000	Prior to reductions in PL 108-7(-$30,046,000 for the enacted rescission and $2,000 lapse). Includes $263,442,000 of AIDS funding.
2004	4,770,519,000	Prior to reductions in PL 108-199(-$3,136,000 for Labor/ HHS/ED rescission; $28,128,000 for across the board reduction; -$15,357,000 NIH 1% transfer assessment, and $5,000 lapse). Includes $266,975,000 of AIDS funding.
2005	4,865,525,000	Prior to reductions in PL 108-447($38,914,000 .8% across the board reduction; -$1,353,000 for Labor/HHS/ED rescission; -$30,505,000 NIH 1% transfer assessment, and $9,000 lapse). Includes $265,907,000 of AIDS funding.
2006	4,841,774,000	Prior to reductions in PL 109-149 (-$48,418,000 for Labor/ HHS/ED rescission; -$3,293,000 HHS transfer for CMS activities; -$42,834,000 NIH 1% transfer for roadmap activities, and $4,000 lapse). Includes $253,666,000 of AIDS funding.
2007	4,797,639,000	Prior to reductions in PL 110-5 (-$5,015,000 NIH transfer for GEI activities, and $9,000 lapse). Includes $253,666,000 of AIDS funding.
2008	4,890,525,000	Prior to -$85,437,000 rescission and $3,091,000 in NIH transfer activities. Includes supplemental appropriation of $25,559,000. Includes $258,499,000 of AIDS funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2009	4,968,973,000	Prior to reductions in PL 111-8 (-$2,042,631 NIH transfer for activities, and $4,000 lapse). Includes $265,882,000 of AIDS funding.
2010	5,103,388,000	Prior to -$760,000 HHS Secretary's transfer, -$4,459,000 in NIH transfer for activities, and $22,000 lapse. Includes $272,130,000 of AIDS funding.
2011	5,103,388,000	Prior to -$44,810,787 recission and $472,000 lapse. Includes $269,953,000 of AIDS funding.
2012	5,081,788,000	Prior to $9,605,579 rescission, -$1,445,000 HHS Secretary's transfer ,-$3,342,000 HHS Secretary's transfer for Alzheimer's research, and $54,000 lapse. Includes $271,692,000 of AIDS funding.
2013	5,072,183,000	Prior to -$254,589,000 under sequestration (Budget Control Act, 2011, PL 112–25), -$10,144,367 recission, -$28,044,000 HHS Secretary's transfer and +$9,714,000 restored from the National Children's Study and National Eye Institute HIV/AIDS funding, and $106,000 lapse. Includes $261,550,000 of AIDS funding.
2014	4,923,238,000	Prior to -$12,359,000 HHS Secretary's transfer,-$965,000 HHS Secretary’s Cybersecurity Transfer (authorized by section 206 of P.L. 113-76), +$16,180,552 transfer from National Children's Study, and +$6,307,000 transfer from NIH Office of AIDS Research, and $33,000 lapse. Includes $269,212,000 of AIDS funding.
2015	4,950,396,000	Prior to +$2,632,000 transfer from NIH Office of AIDS Research and $435,000 lapse. Includes $269,660,000 of AIDS funding.
2016	5,214,701,000	Prior to -$7,217,390 HHS Secretary's transfer, -$1,192,000 transfer to NIH Office of AIDS Research, and $122,000 lapse. Includes $266,422,000 of AIDS funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2017	5,689,329,000	Prior to -$11,971,000 HHS Secretary's transfer, -$17,403,000 transfer to NIH Office of AIDS Research, and $247,000 lapse. Includes $249,019,000 of AIDS funding and $300,000,000 of Cancer Moonshot℠ funding.
2018	5,964,800,000	Prior to -$13,309,000 HHS Secretary's transfer, -$7,785,000 transfer to NIH Office of AIDS Research, and $250,000 lapse. Includes $241,234,000 of AIDS funding and $300,000,000 of Cancer Moonshot℠ funding.
2019	6,143,892,000	Prior to -$19,730,000 HHS Secretary's transfer, -$2,874,000 transfer to NIH Office of AIDS Research, and $252,786 lapse. Includes $241,979,000 of AIDS funding and $400,000,000 of Cancer Moonshot℠ funding.
2020	6,440,442,000	Prior to -$4,000 transfer to NIH Office of AIDS Research, and $254,618 lapse. Includes $241,975,000 of AIDS funding and $195,000,000 of Cancer Moonshot℠ funding.
2021	6,559,852,000	Prior to -$1,047,000 transfer to NIH Office of AIDS Research, Secretary's Transfer -$19,109,000, and $289,223 lapse. Includes $240,513,000 of AIDS funding, and $195,000,000 of Cancer Moonshot℠ funding.
1938 - 2021		

NCI Funding Trends

Funding amounts and percentages reflect actual obligations for each fiscal year.

NCI Funding

FUNDING BY MECHANISM, FY 2017–2021

(Dollars in Millions)

Mechanism	2017**	2018**	2019**	2020**	2021**
Total NCI	**$5,636.4**	**$5,927.7**	**$5,992.3**	**$6,383.3**	**$6,442.7**
Research Project Grants	2,278.4	2,450.6	2,541.7	2,749.4	2,822.4
Cancer Centers	313.0	331.4	337.1	382.0	344.7
SPOREs	111.4	115.8	110.7	113.2	119.6
Other P50s/P20s	1.3	0	7.4	7.9	3.3
Specialized Centers	135.6	178.3	200.8	110.7	95.9
Clinical Cooperative Groups	245.3	255.3	290.1	295.6	300.0
R&D Contracts	880.4	825.4	768.1	823.0	812.2
Intramural Research	899.7	945.5	964.9	1,072.6	1,102.5
Other Mechanisms*	771.2	825.3	771.5	829.0	842.0

**Other mechanisms includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.*

***Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.*

Percent Change by Mechanism

PERCENT CHANGE BY MECHANISM, FY 2017–2021

Mechanism	2016 to 2017	2017 to 2018	2018 to 2019	2019 to 2020	2020 to 2021
Total NCI	**8.3%**	**5.2%**	**1.1%**	**6.5%**	**0.9%**
Research Project Grants	6.2%	7.6%	3.7%	8.2%	2.7%
Cancer Centers	-6.6%	5.9%	1.7%	13.3%	-9.8%
SPOREs	3.0%	3.9%	-4.4%	2.3%	5.6%
Other P50s/P20s	-52.6%	-100.0%	100.0%	6.5%	-58.4%
Specialized Centers	36.5%	31.5%	12.6%	-44.9%	-13.3%
Clinical Cooperative Groups	11.0%	4.1%	13.6%	1.9%	1.5%
R&D Contracts	20.2%	-6.2%	-6.9%	7.1%	-1.3%
Intramural Research	0.6%	5.1%	2.1%	11.2%	2.8%
Other Mechanisms*	15.6%	7.0%	-6.5%	7.5%	1.6%

**Other mechanisms includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.*

***Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.*

Percent Share of Total NCI Dollars

MECHANISM SHARE OF NCI BUDGET, FY 2017–2021

Mechanism	2017	2018	2019	2020	2021
Research Project Grants	40.4%	41.3%	42.4%	43.1%	43.8%
Cancer Centers	5.6%	5.6%	5.6%	6.0%	5.4%
SPOREs	2.0%	2.0%	1.8%	1.8%	1.9%
Other P50s/P20s	0.0%	0.0%	0.1%	0.1%	0.1%
Specialized Centers	2.4%	3.0%	3.4%	1.7%	1.5%
Clinical Cooperative Groups	4.4%	4.3%	4.8%	4.6%	4.7%
R&D Contracts	15.6%	13.9%	12.8%	12.9%	12.6%
Intramural Research	16.0%	16.0%	16.1%	16.8%	17.3%
Other Mechanisms*	13.7%	13.9%	12.9%	13.0%	13.1%

**Other mechanisms includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.*

***Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.*

Extramural vs Intramural and RMS Funding

The following is a comparison broken out by mechanism and total between Extramural dollars spent vs Intramural Research Program (IRP) and Research Management and Support (RMS).



*Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.

View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/historical-trends/extramural-intramural-rms/extramural-vs-ir-and-rms-fy21.xlsx.

FY 2017–2021 TOTAL NCI FUNDING

(Dollars in Millions)

2017*	2018*	2019*	2020*	2021*	2017-2021 % Change
$5,636.4	$5,927.7	$5,992.3	$6,383.4	$6,442.7	14.3%

**Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.*

FY 2017–2021 EXTRAMURAL FUNDING

(Dollars in Millions)

Mechanism	2017*	2018*	2019*	2020*	2021*	2017-2021 % Change
Research Project Grants	$2,278.4	$2,450.6	$2,541.7	$2,749.4	$2,822.4	23.9%
Cancer Centers	313.0	331.4	337.1	382.0	344.7	10.1%
SPOREs	111.4	115.8	110.7	113.2	119.6	7.3%
Other P50s/ P20s	1.3	0.0	7.4	7.9	3.3	147.0%
Other Specialized Centers	135.6	178.3	200.8	110.7	95.9	-29.2%
Other Research Grants	481.9	537.9	506.8	548.1	556.2	15.4%
NRSA	77.6	82.4	87.0	96.4	93.0	19.8%
R&D Contract	880.4	825.4	768.1	823.0	812.2	-7.7%
Buildings & Facilities	30.0	18.0	18.0	30.0	30.0	0.0%
Total Extramural Funds	**$4,309.7**	**$4,539.8**	**$4,577.5**	**$4,860.7**	**$4,877.3**	**13.2%**

**Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.*

FY 2017–2021 INTRAMURAL AND RMS FUNDING

(Dollars in Millions)

Mechanism	2017*	2018*	2019*	2020*	2021*	2017-2021 % Change
Intramural Research	$899.7	$945.5	$964.9	$1,072.6	$1,102.5	22.5%
RMS	427.0	442.4	449.9	450.0	462.9	8.4%
Total IRP & RMS Funds	**$1,326.7**	**$1,387.9**	**$1,414.8**	**$1,522.6**	**$1,565.4**	**18.0%**

**Fiscal years 2017 through 2021 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2021.*

Comparison of Dollars, Positions, and Space

This page presents tables comparing of NCI's budget, full-time equivalent (FTE) positions, and occupied space from fiscal years 2011 through 2021.

In this table, funds represent obligations against the annual appropriation in millions of dollars. Fiscal years 2017 through 2021 figures include the Cancer Moonshot℠ funding. FTEs are the number of work years for appointed employees of the NCI. A work year equals 2,080 hours. Space is in thousands of square feet, excluding NCI-Frederick.

The increase in space (Sq Ft) during FY 2013 is due to NCI's lease of its Shady Grove complex, a new consolidated facility in Rockville, MD. This facility has the advantage of providing additional space for NCI scientific programs, and includes conference and meeting rooms, a cafeteria, and a data center that serves multiple NCI facilities. During FY 2013, NCI was working to decommission their vacated leased facilities, and continued to lease a portion of them while completing the decommissioning process.

The 2016 FTE count has been updated to include Commissioned Corp staff.



View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/historical-trends/comparison/comparison-dollars-position-space-fy21.xlsx.

NCI Personnel

The table below displays NCI-staffing levels, by type of appointment, for fiscal years 2010-2021.

- Full-time equivalents represent 2,080 hours per person employed
- Full-time and part-time appointments include employees from NIH Employment Report 71E
- Training Fellows including visiting fellows, Cancer Research Training Award (CRTA) and the few remaining Intramural Research Training Award (IRTA), biotech, and tech transfers
- Total employees include full-time and part-time permanent tours

Fiscal Year	Full Time Permanent	Other Than Full Time Permanent	Training Fellows	Total Personnel Resources
2010	2,148	1,011	1,073	4,232
2011	2,180	1,029	1,108	4,317
2012	2,139	997	906	4,042
2013	2,173	948	847	3,968
2014	2,139	923	879	3,941
2015	2,119	897	947	3,963
2016	2,050	1,001	972	4,023
2017	2,156	890	1,042	4,088
2018	2,083	845	1,045	3,973
2019	2,101	879	1,061	4,041
2020	2,136	952	1,150	4,143
2021	2,188	1,007	1,133	4,328

The figures for FY 2020 Full Time Permanent Appointment and FY 2020 Other than Full Time Permanent Appointment have been updated to reflect on-board counts rather than utilization rate.

NCI and NIH AIDS Funding History

The NCI has played a major role in HIV/AIDS research since the beginning of the AIDS epidemic. Scientists within and supported by the NCI have made a number of key discoveries. HIV/AIDS research is conducted throughout the Divisions and Offices of the NCI and is coordinated by the NCI Office of HIV and AIDS Malignancy.

In addition, because HIV/AIDS transcends every area of clinical medicine and basic scientific investigation, the NIH AIDS research effort involves every NIH Institute and Center. The NIH Office of AIDS Research has primary responsibility for planning and coordinating AIDS research across the NIH.



View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/historical-trends/aids-funding/aids-funding-fy21.xlsx.

Cancer Moonshot℠ – Recent Fiscal Year Funding

The 21st Century Cures Act, which was signed into law in December 2016, authorized $1.8 billion to fund the Cancer Moonshot over a 7 year period. The goal of the Cancer Moonshot is to accelerate progress in cancer, including prevention and screening, from cutting edge basic research to wider uptake of standard of care.

The following pages contain information on the $195 million of Cancer Moonshot funding received during Fiscal Year 2021.

More information on Cancer Moonshot can be found by visiting the NCI Cancer Moonshot Initiative page.

Information on recent funding opportunity announcements can be found on the Cancer Moonshot Funding Opportunities page.

CANCER MOONSHOT FISCAL YEAR SUMMARY

(Whole Dollars)

Fiscal Year	Authorization
2017	$300,000,000
2018	$300,000,000
2019	$400,000,000
2020	$195,000,000
2021	$195,000,000
2022	$194,000,000
2023	$216,000,000
Total	**$1,800,000,000**

Funding for the Cancer Moonshot is appropriated on an annual basis. The following pages contain information on the initial $195 million of Cancer Moonshot funding received during Fiscal Year 2021.

Cancer Moonshot℠ – Obligations by Budget Mechanism

With over $190 million appropriated for Cancer Moonshot activities in fiscal year (FY) 2021, funding was allocated into four budget mechanisms: research grants, R&D contracts, intramural research, and research management and support, as shown in the chart below.



View the complete data set here: https://www.cancer.gov/about-nci/budget/fact-book/cancer-moonshot/moonshot-obligations/moonshot-obligations-m3-fy21-2.xlsx.

Similar to the institute's annual appropriation, NCI reports Cancer Moonshot obligations by funding mechanism.

FY 2021 CANCER MOONSHOT AND CARRYOVER - OBLIGATIONS BY MECHANISM

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount[1]
Research Project Grants (RPGs)	Competing	7	$1,818,651
	Noncompeting	58	$60,399,839
	Administrative Supplements	20	$4,762,599
	Subtotal, without SBIR	65	$66,981,088
	SBIR/STTR Grants	2	$858,796
	Subtotal, RPGs	**67**	**$67,839,884**
Centers	Cancer Centers Grants-P30s	1	$4,747,685
	P50s	7	$8,382,195
	Cooperative Agreements-U54s/U41s	15	$13,244,735
	Subtotal, Centers	**23**	**$26,374,615**
Other Research	Resource Grants-U24s/ U2Cs	11	$28,722,409
	Subtotal, Other Research	**11**	**$28,722,409**
Subtotal, Research Grants		**103**	**$122,936,908**
Intramural Research	Program	0	$49,648,875
Research Management & Support	RMS	0	$0

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount[1]
R&D Contracts	R&D Contracts	17	$27,393,003
	SBIR/STTR Contracts	7	$6,257,004
	Subtotal, R&D Contracts	**24**	**$33,650,007**
Total			**$206,235,789**

[1] *Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, and 2020 carryover accounts.*

Cancer Moonshot℠ – Funding by Research Category

To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a Blue Ribbon Panel (BRP) of scientific experts as a working group to the National Cancer Advisory board. In September of 2016, the BRP presented a final report outlining 10 research recommendations that represent areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment and care.

The following research categories align with these 10 recommendations:

CANCER MOONSHOT BY CATEGORY, FY 2021

(Whole Dollars)

Research Category	Amount[1]
Network for Direct Patient Engagement	$53,968,535
Cancer Immunotherapy Translational Science Network	$41,061,992
Therapeutic Target Identification to Overcome Drug Resistance	$12,369,888
A National Cancer Data Ecosystem for Sharing and Analysis	$10,646,973
Fusion Oncoproteins in Childhood Cancers	$1,172,420
Minimize Cancer Treatment's Debilitating Side Effects	$8,179,143
Prevention and early detection: Implementation of Evidence-Based Approaches	$41,263,844
Retrospective Analysis of Biospecimens form Patients Treated with Standard of Care	$96
Generation of Human Tumor Atlases	$15,770,950
Development of New Enabling Cancer Technologies	$21,785,549

(Continued from previous page)

Research Category	Amount[1]
Other Cancer Moonshot priority activities (e.g., Partnership for Accelerating Cancer Therapies)	$16,400
Total	**$206,235,789**

[1] *Includes new obligations and recoveries from fiscal years 2017, 2018, 2019 and 2020 carryover accounts.*

NATIONAL CANCER INSTITUTE

cancer.gov